JP2009500357A - 肥満、インスリン抵抗性障害およびミトコンドリア関連障害を処置または予防するための方法および関連する組成物 - Google Patents

肥満、インスリン抵抗性障害およびミトコンドリア関連障害を処置または予防するための方法および関連する組成物 Download PDF

Info

Publication number
JP2009500357A
JP2009500357A JP2008519734A JP2008519734A JP2009500357A JP 2009500357 A JP2009500357 A JP 2009500357A JP 2008519734 A JP2008519734 A JP 2008519734A JP 2008519734 A JP2008519734 A JP 2008519734A JP 2009500357 A JP2009500357 A JP 2009500357A
Authority
JP
Japan
Prior art keywords
compound
sirtuin activating
formula
activating compound
sirtuin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008519734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009500357A5 (https=
Inventor
マイケル ミルバーン，
ジル ミルン，
ヨハン オーウェル，
カルメン アーグマン，
マリー ラゴージュ，
ミシェル ディップ，
Original Assignee
サートリス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サートリス ファーマシューティカルズ， インコーポレイテッド filed Critical サートリス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2009500357A publication Critical patent/JP2009500357A/ja
Publication of JP2009500357A5 publication Critical patent/JP2009500357A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
JP2008519734A 2005-07-07 2006-07-07 肥満、インスリン抵抗性障害およびミトコンドリア関連障害を処置または予防するための方法および関連する組成物 Pending JP2009500357A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69744305P 2005-07-07 2005-07-07
US73652805P 2005-11-14 2005-11-14
US75360605P 2005-12-23 2005-12-23
US78380206P 2006-03-16 2006-03-16
PCT/US2006/026272 WO2007008548A2 (en) 2005-07-07 2006-07-07 Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders

Publications (2)

Publication Number Publication Date
JP2009500357A true JP2009500357A (ja) 2009-01-08
JP2009500357A5 JP2009500357A5 (https=) 2009-08-20

Family

ID=37492426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008519734A Pending JP2009500357A (ja) 2005-07-07 2006-07-07 肥満、インスリン抵抗性障害およびミトコンドリア関連障害を処置または予防するための方法および関連する組成物

Country Status (6)

Country Link
EP (1) EP1898897A2 (https=)
JP (1) JP2009500357A (https=)
CN (1) CN103055313A (https=)
AU (1) AU2006269459B2 (https=)
CA (1) CA2613141A1 (https=)
WO (1) WO2007008548A2 (https=)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011107130A (ja) * 2009-10-19 2011-06-02 Kumamoto Univ インドキシル硫酸の産生の阻害剤のスクリーニング方法、インドキシル硫酸代謝産生阻害剤、及び腎障害軽減剤
WO2011096414A1 (ja) * 2010-02-03 2011-08-11 花王株式会社 ミトコンドリア機能向上剤
WO2012026491A1 (ja) * 2010-08-26 2012-03-01 国立大学法人京都大学 多能性幹細胞の心筋分化促進剤
WO2012036168A1 (ja) * 2010-09-14 2012-03-22 北海道公立大学法人札幌医科大学 筋ジストロフィーを処置するための組成物
WO2013051459A1 (ja) * 2011-10-02 2013-04-11 キユーピー 株式会社 ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途
WO2013111875A1 (ja) * 2012-01-27 2013-08-01 国立大学法人京都大学 多能性幹細胞の心筋分化誘導法
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
JP2016516040A (ja) * 2013-03-15 2016-06-02 ニューサート サイエンシーズ， インコーポレイテッド 脂質レベルを低下させるロイシンおよびニコチン酸
US9499790B2 (en) 2010-08-26 2016-11-22 Kyoto University Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells
JP2017160258A (ja) * 2011-07-15 2017-09-14 ニューサート サイエンシーズ， インコーポレイテッド 代謝経路を変調させるための組成物および方法
JP2018172346A (ja) * 2017-03-31 2018-11-08 株式会社東洋新薬 妊娠サポート用組成物
US10196609B2 (en) 2013-03-08 2019-02-05 Kyoto University Composition for promoting cardiac differentiation of pluripotent stem cell comprising EGFR inhibitor
US10233426B2 (en) 2014-05-30 2019-03-19 Kyoto University Method for inducing cardiac differentiation of pluripotent stem cell with low-molecular compounds
JPWO2018079719A1 (ja) * 2016-10-27 2019-09-19 サントリーホールディングス株式会社 ＰＧＣ−１α活性化用組成物
US10646489B2 (en) 2012-11-13 2020-05-12 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
AU2006218403A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
ES2524922T3 (es) 2005-05-10 2014-12-15 Intermune, Inc. Derivados de piridona para modular el sistema de proteína cinasa activada por estrés
WO2007049796A2 (en) * 2005-10-26 2007-05-03 Kao Corporation Resveratrol and/or grape leaf extract as i. a. endurance improver, anti-aging agent, muscle strength improver
US7968711B2 (en) 2006-04-24 2011-06-28 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US7718830B2 (en) 2006-04-24 2010-05-18 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US7612101B2 (en) 2006-04-24 2009-11-03 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US7618966B2 (en) 2006-04-24 2009-11-17 Allergan, Inc. Abnormal Cannabidiols as agents for lowering intraocular pressure
US8778986B1 (en) * 2007-01-25 2014-07-15 University Of South Florida Treatment of glycogen synthase kinase-based disease
US8802638B1 (en) * 2007-01-25 2014-08-12 University Of South Florida Flavonoid treatment of glycogen synthase kinase-based disease
EP2124985A4 (en) * 2007-01-26 2011-06-08 Univ Washington METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS
US20100130597A1 (en) 2007-07-06 2010-05-27 The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service Dna-pkcs modulates energy regulation and brain function
WO2009054994A2 (en) * 2007-10-23 2009-04-30 President And Fellows Of Harvard College Sirt-3 related methods and compositions for mimicking exercise
EA021938B1 (ru) 2008-05-01 2015-10-30 Сертрис Фармасьютикалз, Инк. Хинолины и их аналоги в качестве модуляторов сиртуина
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
AU2009266889B2 (en) 2008-07-03 2013-05-02 Glaxosmithkline Llc Benzimidazoles and related analogs as sirtuin modulators
WO2010020959A1 (en) * 2008-08-21 2010-02-25 University Of Cape Town Resveratrol-containing composition for treating heart failure
US9326986B2 (en) 2008-09-29 2016-05-03 Glaxosmithkline Llc Quinazolinone, quinolone and related analogs as sirtuin modulators
US9556201B2 (en) 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
DK2496594T3 (en) * 2009-11-06 2018-03-05 The J David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS
WO2012008549A1 (ja) * 2010-07-15 2012-01-19 武田薬品工業株式会社 複素環化合物
US9861116B2 (en) * 2010-12-20 2018-01-09 Hill's Pet Nutrition, Inc. Pet food compositions for inducing a satiety response
AU2015201811B2 (en) * 2010-12-20 2016-09-29 Hill's Pet Nutrition, Inc. Pet food compositions for inducing a satiety response
MX336980B (es) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
EP2699236B1 (en) * 2011-04-22 2018-06-20 Napo Pharmaceuticals Inc Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga)
EP3345901A3 (en) * 2011-06-29 2018-09-12 President and Fellows of Harvard College Small molecules as antiaging agents
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
EP2872128B1 (en) 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
WO2014014816A2 (en) * 2012-07-17 2014-01-23 Ngm Biopharmaceuticals, Inc. Methods of treating glucose metabolism disorders
WO2014014819A2 (en) * 2012-07-17 2014-01-23 Ngm Biopharmaceuticals, Inc. Methods of treating glucose metabolism disorders
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014199171A1 (en) * 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
US20160101072A1 (en) * 2013-06-12 2016-04-14 Proximagen Limited Therapeutic uses of enzyme inhibitors
KR20220098049A (ko) * 2013-10-30 2022-07-08 크로마덱스 아이엔씨. 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
US9370503B1 (en) * 2015-02-26 2016-06-21 Chi Chou Liao Compounds for treating ocular diseases
WO2016158212A1 (ja) * 2015-03-31 2016-10-06 新興和製薬株式会社 レスベラトロールとニコチンアミドモノヌクレオチドを含む食品組成物
WO2017042198A2 (en) * 2015-09-08 2017-03-16 Ecole Polytechnique Federale De Lausanne (Epfl) Agents and methods using thereof for the prevention and treatment of stem cell muscle disorders
AU2016375177B2 (en) * 2015-12-24 2022-09-01 Amazentis Sa Compositions comprising nicotinamide riboside and a urolithin
WO2018002215A1 (en) * 2016-06-30 2018-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
CN108066348A (zh) * 2016-11-16 2018-05-25 成都普睿法药物研发有限公司 土大黄苷在制备抗肺纤维化药物中的应用
CN106580951B (zh) * 2016-11-17 2019-07-30 珠海雅光生物工程有限公司 一种黄烷酮化合物的新用途
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
EP3388072A1 (en) * 2017-04-10 2018-10-17 Universität Leipzig Ubiquinone-independent cytoplasmic dihydroorotate dehydrogenase for use as medicament
ES3004332T3 (en) * 2017-05-17 2025-03-12 Univ De Valencia Estudi General Treating and preventing amyotrophic lateral sclerosis with nicotinamide riboside and pterostilbene
WO2019043846A1 (ja) 2017-08-30 2019-03-07 大塚製薬株式会社 ケンペロール類縁体含有組成物
CN109896997A (zh) * 2017-12-08 2019-06-18 中国药科大学 N－酰基苯胺类c－Met激酶抑制剂的制备方法及其用途
WO2019143560A1 (en) * 2018-01-16 2019-07-25 The Regents Of The University Of California Methods for promoting mitochondrial biogenesis in neural cells
PH12021551300A1 (en) * 2018-12-05 2022-03-28 Celagenex Res India Pvt Ltd Synergistic compositions of bioactive agents for optimizing cellular health
KR102712818B1 (ko) 2018-12-06 2024-09-30 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
CA3153108A1 (en) * 2019-10-08 2021-04-15 Riccardo Perfetti Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency
CN112516138B (zh) * 2020-12-15 2022-03-29 中国人民解放军陆军军医大学 化合物yx-2102在制备治疗肺纤维化药物中的应用
WO2022129490A1 (en) 2020-12-18 2022-06-23 Nuvamid Sa Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of a red blood cell disorder
CN117580573A (zh) * 2021-06-22 2024-02-20 南京纽邦生物科技有限公司 L-麦角硫因用于缓解和预防年龄相关的视力退化
CN116390716A (zh) * 2021-06-22 2023-07-04 南京纽邦生物科技有限公司 L-麦角硫因用于改善和预防年龄相关的玻璃体变性
CN113663083A (zh) * 2021-08-16 2021-11-19 重庆第二师范学院 一种漆黄素磷脂复合物和减肥药物/保健食品及其应用
CN114668845B (zh) * 2022-04-06 2023-04-11 北京清华长庚医院 肝脏Sirt5蛋白在制备抑制糖异生和提高糖耐量的产品中的应用
CN114920805B (zh) * 2022-05-06 2022-12-06 浙江湃肽生物股份有限公司 一种具有改善皱纹活性的新型红蝎毒素及包含其的组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001072583A (ja) * 1999-09-07 2001-03-21 Sunstar Inc 高脂血症の予防又は治療用組成物
WO2004105517A1 (en) * 2003-05-27 2004-12-09 Dsm Ip Assets B.V. Novel nutraceutical compositions and use thereof
WO2005002672A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
WO2002081651A2 (en) * 2001-02-20 2002-10-17 Uab Research Foundation Polyphenolics for enhancing endothelial cell-mediated fibrinolysis
MXPA04000834A (es) * 2002-05-27 2005-08-26 Advance Holdings Ltd Suplementos dieteticos de vinasa de vino y un proceso importante de produccion.
EP1708689A2 (en) * 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US7714161B2 (en) * 2004-01-20 2010-05-11 Brigham Young University Sirtuin activating compounds and methods for making the same
CN1956733B (zh) * 2004-04-07 2012-10-10 白藜芦醇合伙人有限责任公司 营养补充剂及其加工方法
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001072583A (ja) * 1999-09-07 2001-03-21 Sunstar Inc 高脂血症の予防又は治療用組成物
WO2004105517A1 (en) * 2003-05-27 2004-12-09 Dsm Ip Assets B.V. Novel nutraceutical compositions and use thereof
JP2006528950A (ja) * 2003-05-27 2006-12-28 ディーエスエム アイピー アセッツ ビー．ブイ． 新規栄養補助食品組成物及びその使用
WO2005002672A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
JP2007530417A (ja) * 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞及び生物の寿命及びストレス応答を操作するための組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6012021073; ＤＥＮＧ，Ｊ．　ｅｔ　ａｌ: 'Ａｎｔｉ-ｄｉａｂｅｔｉｃ　ａｃｔｉｖｉｔｙ　ｏｆ　ｒｅｓｖｅｒａｔｒｏｌ，　ａ　ｎａｔｕｒａｌ　ａｎｔｉｏｘｉｄａｎｔ　ｄｅｒｉｖｅｄ　ｆｒｏｍ　ｇｒａｐｅｓ' ＦＡＳＥＢ　Ｊｏｕｒｎａｌ Ｖｏｌ．１９，　Ｎｏ．４, 200503, ｐ．Ａ６３４ *
JPN6012021076; ＳＵ，Ｈ．　ｅｔ　ａｌ: 'Ｒｅｓｖｅｒａｔｒｏｌ　ｐｏｓｓｅｓｓｅｓ　ｈｙｐｏｇｌｙｃｅｍｉｃ　ｅｆｆｅｃｔ　ｉｎ　ＳＴＺ-ｉｎｄｕｃｅｄ　ＩＤＤＭ　ｒａｔｓ' ＦＡＳＥＢ　Ｊｏｕｒｎａｌ Ｖｏｌ．１９，　Ｎｏ．５, 200503, ｐ．Ａ１６８１-Ａ１６８２ *
JPN6012021077; ＢＯＲＲＡ，Ｍ．Ｔ．　ｅｔ　ａｌ: 'Ｍｅｃｈａｎｉｓｍ　ｏｆ　ｈｕｍａｎ　ＳＩＲＴ１　ａｃｔｉｖａｔｉｏｎ　ｂｙ　ｒｅｓｖｅｒａｔｒｏｌ' Ｊ　Ｂｉｏｌ　Ｃｈｅｍ Ｖｏｌ．２８０，　Ｎｏ．１７, 2005, ｐ．１７１８７-９５ *
JPN6012021079; 'Ｎｕｔｒｉｅｎｔ　ｃｏｎｔｒｏｌ　ｏｆ　ｇｌｕｃｏｓｅ　ｈｏｍｅｏｓｔａｓｉｓ　ｔｈｒｏｕｇｈ　ａ　ｃｏｍｐｌｅｘ　ｏｆ　ＰＧＣ-１ａｌｐｈａ　ａｎｄ　ＳＩＲＴ１' Ｎａｔｕｒｅ Ｖｏｌ．４３４，　Ｎｏ．７０２９, 2005, ｐ．１１３-８ *
JPN6012021081; ＢＩＥＧＡＮＯＷＳＫＩ，Ｐ．　ｅｔ　ａｌ: 'Ｄｉｓｃｏｖｅｒｉｅｓ　ｏｆ　ｎｉｃｏｔｉｎａｍｉｄｅ　ｒｉｂｏｓｉｄｅ　ａｓ　ａ　ｎｕｔｒｉｅｎｔ　ａｎｄ　ｃｏｎｓｅｒｖｅｄ　ＮＲＫ　ｇｅｎｅｓ　ｅｓｔａｂｌｉｓｈ　ａ　Ｐｒｅｉｓｓ-Ｈａｎｄｌｅ' Ｃｅｌｌ Ｖｏｌ．１１７，　Ｎｏ．４, 2004, ｐ．４９５-５０２ *
JPN6012021083; ＲＥＩＤ，Ｍ．Ｂ．　ｅｔ　ａｌ: 'Ｒｅａｃｔｉｖｅ　ｏｘｙｇｅｎ　ｉｎ　ｓｋｅｌｅｔａｌ　ｍｕｓｃｌｅ．　Ｉ．　Ｉｎｔｒａｃｅｌｌｕｌａｒ　ｏｘｉｄａｎｔ　ｋｉｎｅｔｉｃｓ　ａｎｄ　ｆａｔｉｇｕｅ　ｉｎ　ｖｉｔｒｏ' Ｊ　Ａｐｐｌ　Ｐｈｙｓｉｏｌ Ｖｏｌ．７３，　Ｎｏ．５, 1992, ｐ．１７９７-８０４ *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011107130A (ja) * 2009-10-19 2011-06-02 Kumamoto Univ インドキシル硫酸の産生の阻害剤のスクリーニング方法、インドキシル硫酸代謝産生阻害剤、及び腎障害軽減剤
WO2011096414A1 (ja) * 2010-02-03 2011-08-11 花王株式会社 ミトコンドリア機能向上剤
WO2012026491A1 (ja) * 2010-08-26 2012-03-01 国立大学法人京都大学 多能性幹細胞の心筋分化促進剤
US9499790B2 (en) 2010-08-26 2016-11-22 Kyoto University Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells
US8658425B2 (en) 2010-08-26 2014-02-25 Kyoto University Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells
JP5930205B2 (ja) * 2010-08-26 2016-06-08 国立大学法人京都大学 多能性幹細胞の心筋分化促進剤
JP5850503B2 (ja) * 2010-09-14 2016-02-03 北海道公立大学法人 札幌医科大学 筋ジストロフィーを処置するための組成物
WO2012036168A1 (ja) * 2010-09-14 2012-03-22 北海道公立大学法人札幌医科大学 筋ジストロフィーを処置するための組成物
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
JP2017160258A (ja) * 2011-07-15 2017-09-14 ニューサート サイエンシーズ， インコーポレイテッド 代謝経路を変調させるための組成物および方法
US10383837B2 (en) 2011-07-15 2019-08-20 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
US10076507B1 (en) 2011-07-15 2018-09-18 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
WO2013051459A1 (ja) * 2011-10-02 2013-04-11 キユーピー 株式会社 ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途
JPWO2013051459A1 (ja) * 2011-10-02 2015-03-30 キユーピー株式会社 ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途
WO2013111875A1 (ja) * 2012-01-27 2013-08-01 国立大学法人京都大学 多能性幹細胞の心筋分化誘導法
US9587220B2 (en) 2012-01-27 2017-03-07 Kyoto University Method for inducing cardiac differentiation of pluripotent stem cell
JPWO2013111875A1 (ja) * 2012-01-27 2015-05-11 国立大学法人京都大学 多能性幹細胞の心筋分化誘導法
US10646489B2 (en) 2012-11-13 2020-05-12 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
US10196609B2 (en) 2013-03-08 2019-02-05 Kyoto University Composition for promoting cardiac differentiation of pluripotent stem cell comprising EGFR inhibitor
JP2016516040A (ja) * 2013-03-15 2016-06-02 ニューサート サイエンシーズ， インコーポレイテッド 脂質レベルを低下させるロイシンおよびニコチン酸
US10233426B2 (en) 2014-05-30 2019-03-19 Kyoto University Method for inducing cardiac differentiation of pluripotent stem cell with low-molecular compounds
JPWO2018079719A1 (ja) * 2016-10-27 2019-09-19 サントリーホールディングス株式会社 ＰＧＣ−１α活性化用組成物
JP2018172346A (ja) * 2017-03-31 2018-11-08 株式会社東洋新薬 妊娠サポート用組成物

Also Published As

Publication number Publication date
EP1898897A2 (en) 2008-03-19
AU2006269459B2 (en) 2013-02-07
AU2006269459A1 (en) 2007-01-18
WO2007008548A3 (en) 2007-08-09
WO2007008548A2 (en) 2007-01-18
CN103055313A (zh) 2013-04-24
CA2613141A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
AU2006269459B2 (en) Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070149466A1 (en) Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070248590A1 (en) Modulators of CDC2-like kinases (CLKS) and methods of use thereof
CN101257897A (zh) 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
US20110009496A1 (en) Resveratrol formulations
US10485814B2 (en) Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
AU2006204699B2 (en) Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
US7998974B2 (en) Fused heterocyclic compounds and their use as sirtuin modulators
US20150175645A1 (en) Nicotinamide riboside and analogues thereof
JP2008535790A (ja) サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体
JP2009503114A (ja) サーチュインモジュレーターとしてのベンゾチアゾールおよびチアゾロピリジン
WO2006094209A2 (en) N-benzimidazolylalkyl-substituted amide sirtuin modulators
WO2009085226A2 (en) Inhibitors of cdc2-like kinases (clks) and methods of use thereof
WO2006094210A2 (en) Tetrahydroquinoxalinone sirtuin modulators
WO2006094246A2 (en) N-arylmethyl benzamide sirtuin modulators
WO2006094233A1 (en) N,n'-dicyclic isothiourea sirtuin modulators
WO2006094248A1 (en) Aryl-substituted cyclic sirtuin modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100624

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120223

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120724

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120821

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120921

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130507